Intech Investment Management LLC Sells 8,339 Shares of Lantheus Holdings, Inc. $LNTH

Key Points

• Intech Investment Management LLC reduced its holdings in Lantheus Holdings, Inc. by 9.5%, decreasing its shares to 79,128 after selling 8,339 shares during the first quarter.
• Other large investors have increased their stakes in Lantheus, with Signaturefd LLC raising its position by 36.5% and Quarry LP growing its stake by 2,350.0% in the same period.
• Lantheus reported earnings of $1.57 per share, missing the consensus estimate of $1.65, and had revenue of $378.05 million, down 4.1% year-over-year.

Intech Investment Management LLC decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 9.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 79,128 shares of the medical equipment provider's stock after selling 8,339 shares during the quarter. Intech Investment Management LLC owned about 0.11% of Lantheus worth $7,723,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of LNTH. Signaturefd LLC grew its holdings in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 116 shares during the period. Quarry LP raised its holdings in shares of Lantheus by 2,350.0% during the first quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock valued at $48,000 after purchasing an additional 470 shares during the period. Hughes Financial Services LLC bought a new position in shares of Lantheus during the 1st quarter worth about $81,000. UMB Bank n.a. grew its stake in shares of Lantheus by 68.2% in the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 381 shares during the period. Finally, Blue Trust Inc. increased its position in Lantheus by 117.7% in the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after buying an additional 633 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Mizuho dropped their price target on Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, August 7th. William Blair restated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. JMP Securities cut their price target on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Truist Financial set a $63.00 price objective on Lantheus and gave the stock a "hold" rating in a research report on Monday, August 11th. Finally, B. Riley decreased their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research report on Monday, June 23rd. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $91.60.

Insider Activity

In other news, insider Rajiv A. Patel sold 3,365,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,812,000 shares of company stock worth $382,427,380. Company insiders own 2.00% of the company's stock.

Lantheus Stock Performance

Lantheus stock traded down $2.05 during midday trading on Friday, reaching $52.94. The stock had a trading volume of 842,370 shares, compared to its average volume of 1,488,169. The firm has a market capitalization of $3.60 billion, a PE ratio of 14.08 and a beta of 0.15. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $118.21. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. The firm's 50-day moving average price is $63.98 and its 200 day moving average price is $81.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.08). The business had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business's revenue for the quarter was down 4.1% on a year-over-year basis. During the same period last year, the firm earned $1.80 EPS. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.